The approval of two kinase-targeting drugs, Genentech's trastuzumab (Herceptin®) in 1998 and Novartis's imatinib (Gleevec®) in 2001, and their success as cancer therapeutics, validate the trend ...
analyses of variance and t test use for data analyses. Aldolase increased 36 h after activity than after activity time in experimental group, but in control group it was reverted. There is a ...